Urine-Based Molecular Test Detects Bladder Cancer Quickly and Accurately
By LabMedica International staff writers Posted on 14 Mar 2023 |
Flexible cystoscopy, an invasive procedure involving the insertion of a camera into the bladder, is currently the main technique used to identify bladder cancer tumors. However, this process can be uncomfortable and expensive for patients, and the majority of these cystoscopies result in no abnormalities or malignancies being detected. Now, a new urine-based molecular test can rapidly and precisely detect bladder cancer, thereby streamlining diagnosis and minimizing the necessity for invasive procedures like cystoscopies.
A collaboration between the University of Birmingham (Birmingham, UK) researchers and liquid biopsy cancer detection and screening company Nonacus (Birmingham, UK) has resulted in a novel test for the non-invasive detection of bladder cancer. The GALEAS Bladder from Nonacus is a non-invasive, urine-based diagnostic test designed to provide a sample-to-report molecular triage for patients exhibiting symptoms of hematuria (blood in urine). The urine-based molecular biomarker provides a highly sensitive test that enables the rapid and precise detection of bladder cancer, thus enhancing diagnosis and eliminating the need for invasive cystoscopies.
The test combines highly sensitive liquid biopsy technology with a panel of biomarkers to detect the presence of bladder cancer by locating DNA from tumor cells in urine. The biomarker panel has been validated by the researchers in more than 600 patient samples from three UK clinical cohorts. Their analysis has shown the test to have a high diagnostic accuracy (sensitivity >90%, specificity >85%) across all grades and stages of bladder cancer. The test could potentially work across the entire bladder cancer patient pathway, reducing dependence on invasive cystoscopy and expensive imaging for non-muscle-invasive bladder cancer surveillance and minimal residual disease monitoring, as well as triage for hematuria.
“We are very excited to launch GALEAS Bladder,” said Chis Sale, CEO of Nonacus. “We are striving to develop a suite of meaningful non-invasive tools that can have real impact on the diagnosis and treatment of patients with suspected cancer. GALEAS Bladder represents the first in this pipeline, helping to improve patients' lives and reducing the burden of cystoscopy on overstretched clinics.”
Related Links:
University of Birmingham
Nonacus
Latest Molecular Diagnostics News
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection